Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KID-BID twice-daily Siklos Paediatric in children with sickle cell disease
2024-513750-30-00Phase 2Authorised
- Sponsor
- Theravia
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in sickle cell disease (SCD), sponsored by Theravia. Planned start Jan 2025; status: authorised.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-513750-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513750-30-00.